England HPV Vaccine Study Finds Zero Cervical Cancer Deaths Among Women Aged 20 to 24

A new analysis of cervical cancer mortality in England has put a hard number on one of public health's biggest promises to young women: no cervical cancer deaths were recorded among women aged 20 to 24 between 2020 and 2024.

The finding comes from research published in The Lancet and reported by Gavi's VaccinesWork, which said England's HPV vaccination programme is estimated to have already prevented around 200 cervical cancer deaths. The result is especially important because the first cohorts offered routine HPV vaccination as teenagers are now old enough for researchers to measure mortality outcomes, not only infection or pre-cancer changes.

The HPV vaccine was introduced to prevent infection with high-risk human papillomaviruses, which are linked to almost all cervical cancer cases. The latest analysis looked at national mortality data and compared age groups with different levels of vaccine access. It found major reductions among vaccinated cohorts and no cervical cancer deaths among women aged 20 to 24 in the most recent five-year follow-up period.

For women and families, the headline is simple, but the policy lesson is more complicated. The same reports that celebrated the mortality milestone also warned that vaccination coverage has slipped. Gavi noted expert concern that England is below the World Health Organization target needed to eliminate cervical cancer as a public health problem. The Guardian reported that uptake has fallen from earlier levels, with London especially low compared with the national average.

That makes the story less a declaration of victory than a warning about maintaining the conditions that produced it. Vaccination programmes work when access is easy, trust is high and teenagers receive the vaccine before exposure to HPV. Cervical screening also remains important because the vaccine does not remove every risk and many women were not vaccinated as adolescents.

The study also lands at a time when women's health advocates are asking governments to treat prevention as seriously as treatment. Cervical cancer is largely preventable when vaccination, screening and timely treatment work together. But prevention systems can quietly weaken if appointments are missed, school programmes lose reach, or public health messaging fails to reach communities with lower uptake.

That equity issue matters because public health averages can hide who is being left behind. A national vaccination rate may look acceptable while particular cities, schools or communities fall well below the level needed for broad protection. The study's achievement therefore belongs not just to science, but to delivery: school-based programmes, reminders, catch-up access, trusted clinicians and clear information for parents and teenagers.

For SheMeansNews readers, the practical significance is that a generation of young women in England is showing what successful prevention can look like. A cancer that has historically killed women in early adulthood is becoming far rarer in vaccinated groups. The risk now is complacency. If vaccination rates continue to fall, the gains measured in this study could become harder to sustain.

The strongest reading of the research is therefore both hopeful and urgent. The HPV vaccine is saving lives, but the next phase depends on governments, schools, clinicians and communities keeping uptake high enough that future cohorts of girls and young women receive the same protection.